# Shield Therapeutics: Accrufer® launch on schedule

- Link: https://www.directorstalkinterviews.com/shield-therapeutics-accrufer%c2%ae-launch-on-schedule/412993423
- Published: 2021-05-26T13:26:34+01:00
- Author: Amilia Stone

**Shield Therapeutics plc** (LON:STX) is a commercial-stage pharmaceutical company
delivering specialty products that address patients’ unmet medical needs, with an
initial focus on treating iron deficiency (ID). Feraccru®/Accrufer® has been approved
by the regulators in both Europe and the US. Following completion of a capital increase
in March 2021 to raise the necessary funds, momentum has picked up significantly
in preparing for the US launch of Accrufer, which is due around the end of June.
Even on conservative forecasts with respect to the speed and quantum of market penetration,
Shield is forecast to become profitable in 2023.

 * **Strategy:** Outside the US, Shield’s strategy is to out-license commercialisation
   rights to partners with appropriate expertise in target markets, which has been
   successfully achieved in Europe and China. In the US, Shield has decided to sell
   Accrufer itself, thereby retaining a greater share of the profits for shareholders.
 * **Accrufer launch:** The board decided that it was in shareholders’ best interests
   to launch Accrufer into the US market by itself, generating greater value than
   with a licensing deal. Following the capital increase, Shield has accelerated
   its detailed planning and logistics and remains on schedule to launch in June.
 * **Valuation:** DCF-modelling each of the three main income streams – the US, 
   Europe and China – generates an NPV, which, summed together, gives an EV for 
   the group of $852m/£608m, or 281p per share. The current share price is clearly
   applying a very heavy discount for the execution risk associated with Accrufer.
 * **Risks:** While there remains regulatory risk in China, Feraccru/Accrufer has
   been de-risked by regulatory approvals in Europe and the US. There is execution
   risk associated with Shield’s go-it-alone strategy in the US, but recruitment
   of an experienced team of US commercial managers addresses and minimises this.
 * **Investment summary:** The Shield Therapeutics-led launch of Accrufer was always
   the best option, in our opinion. Although the fundraise was dilutive for shareholders,
   they were all invited to participate. Now that the period of uncertainty is over,
   coupled with the listing on the OTCQX market in the US to raise awareness and
   improve liquidity, we are starting to see a recovery in the shares. The actual
   launch of Accrufer in June will be the next catalyst to narrow the valuation 
   disconnect.

[DOWNLOAD THE FULL REPORT](https://www.hardmanandco.com/research/corporate-research/accrufer-launch-on-schedule/?dm_i=49CL,12SXG,6NAI95,4WEEA,1#report-download)

Share on:
